Efficacy and safety of low dose oral iron for anaemia in IBD (CAESAR)
Research type
Research Study
Full title
A Pilot Study to assess the efficacy and safety of reduced dose oral iron in the treatment of iron deficiency anaemia in inflammatory bowel disease patients
IRAS ID
204608
Contact name
Sreedhar Subramanian
Contact email
Sponsor organisation
Royal Liverpool University Hospital
Eudract number
2018-002982-20
Duration of Study in the UK
3 years, 0 months, 1 days
Research summary
Anaemia (low blood count) is common in patients with inflammatory bowel disease(IBD). This is commonly due to a deficiency of iron. Treatment with oral iron supplements at standard doses may help to correct the blood count to normal but has previously been thought to potentially aggravate IBD symptoms. As a result, intravenous iron has been recommended but this is expensive and no more effective. Earlier studies have shown that low dose oral iron can be effective in restoring blood counts in other patient population such as elderly and pregnant patients whilst reducing the incidence of gastrointestinal side effects. This strategy has not been tried in IBD patients.
We are proposing a pilot study to ascertain the optimal 'reduced' dose of oral iron (liquid ferrous fumarate) in patients with IBD whilst simultaneously assessing its tolerability and assessing changes in stool bacteria. We hope our findings in this preliminary study will help inform the sample size for a larger study
REC name
East Midlands - Derby Research Ethics Committee
REC reference
19/EM/0146
Date of REC Opinion
20 Sep 2019
REC opinion
Further Information Favourable Opinion